NCT03071328
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +17 more
- Locations
-
- Duke University Medical Center Durham, North Carolina, United States
Clinical trial condition
Metastatic Urothelial Carcinoma
Explore clinical trials studying Metastatic Urothelial Carcinoma. Study availability and eligibility vary by location and protocol.
53 public trials
18 recruiting studies
Metastatic Urothelial Carcinoma trial results
NCT02351739
- Conditions
- Carcinoma, Carcinoma, Transitional Cell, Metastatic Urothelial Carcinoma, +3 more
- Locations
-
- University of Chicago Chicago, Illinois, United States
- University of Michigan Ann Arbor, Michigan, United States
- Durham, North Carolina, United States
- James Cancer Hospital Columbus, Ohio, United States
Active, Not Recruiting
Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer
NCT03744793
- Conditions
- Carcinoma, Carcinoma, Transitional Cell, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, +9 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Active, Not Recruiting
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
NCT04579224
- Conditions
- Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +17 more
- Locations
-
- Kingman Regional Medical Center Kingman, Arizona, United States
- Cancer Center at Saint Joseph's Phoenix, Arizona, United States
- Mercy Hospital Fort Smith Fort Smith, Arkansas, United States
- CHI Saint Vincent Cancer Center Hot Springs Hot Springs, Arkansas, United States
Active, Not Recruiting
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
NCT03854474
- Conditions
- Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +16 more
- Locations
-
- Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
- Mayo Clinic in Arizona Scottsdale, Arizona, United States
- Smilow Cancer Hospital-Derby Care Center Derby, Connecticut, United States
- Smilow Cancer Hospital Care Center-Fairfield Fairfield, Connecticut, United States
Active, Not Recruiting
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
NCT04514484
- Conditions
- Adenocarcinoma, Adnexal Diseases, Advanced Differentiated Thyroid Gland Carcinoma, +141 more
- Locations
-
- Northwestern University Chicago, Illinois, United States
- Montefiore Medical Center-Einstein Campus The Bronx, New York, United States
- University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States
Active, Not Recruiting
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
NCT04388852
- Conditions
- Adenocarcinoma, Aggressive Variant Prostate Carcinoma, Carcinoma, +34 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Active, Not Recruiting
Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy
NCT04963153
- Conditions
- Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +36 more
- Locations
-
- Los Angeles General Medical Center Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
- UCHealth University of Colorado Hospital Aurora, Colorado, United States
- Moffitt Cancer Center Tampa, Florida, United States
Active, Not Recruiting
Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations
NCT03047213
- Conditions
- Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +18 more
- Locations
-
- Los Angeles General Medical Center Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
- Keck Medical Center of USC Pasadena Pasadena, California, United States
- University of California Davis Comprehensive Cancer Center Sacramento, California, United States
Active, Not Recruiting
Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma
NCT05154994
- Conditions
- Carcinoma, Carcinoma, Transitional Cell, Infiltrating Urothelial Carcinoma, Sarcomatoid Variant, +6 more
- Locations
-
- Huntsman Cancer Institute/University of Utah Salt Lake City, Utah, United States